INSY Insys Therapeutics Inc.

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Has Filed in U.S. District Court to Recover Losses Suffered by Investors in INSYS Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--

The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired shares of INSYS Therapeutics, Inc. (“INSYS”) (NASDAQ:INSY) between February 23, 2016 and March 15, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Erdmann v. INSYS Therapeutics, Inc., et al. (Case No. 1:17-cv-02225) in the USDC for the Southern District of New York. Click here to view the complaint. To get more information go to:

http://www.zlk.com/pslra/insys-therapeutics-inc-2

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) INSYS had overstated its 2015 net revenue; (2) INSYS had misstated its sales allowances for 2016; (3) accordingly, the Company lacked effective internal controls over financial reporting; and (4) as a result, INSYS public statements were materially false and misleading at all relevant times.

Take Action: if you suffered a loss in INSYS you have until May 16, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
13/04/2017

Underlying

INSYInsys Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Insys Therapeutics Inc.

 PRESS RELEASE
Free
INSY Insys Therapeut...

FDA Accepts New Drug Application for INSYS Therapeutics’ Naloxone Na...

FDA Accepts New Drug Application for INSYS Therapeutics’ Naloxone Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose PHOENIX, July 03, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (OTCMKTS: INSYQ), announced today that its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational, proprietary naloxone nasal spray for the emergency treatment of known or suspected opioid overdose in both adult and pediatric patients has been accepted for filing.  INSYS’ naloxone nasal spray is a single unit dose spray device that delive...

July 3, 2019 1 EN
 PRESS RELEASE
Free
INSY Insys Therapeut...

INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Mo...

INSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions Operations to Continue in the Ordinary Course During Court-Supervised Process PHOENIX, June 12, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY) (“INSYS” or the “Company”), a specialty pharmaceutical development and distribution company, announced that on June 11, 2019 INSYS received interim approvals from the U.S. Bankruptcy Court for the District of Delaware for its First Day motions related to the Chapter 11 petitions filed on June 10, 2019. Andrew G. Long, Chief Executive Officer of INSYS Therap...

June 12, 2019 1 EN
 PRESS RELEASE
Free
INSY Insys Therapeut...

INSYS Therapeutics Initiates Court-Supervised Process to Facilitate As...

INSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities Company to Facilitate Transaction Process and Sale of Substantially All Assets Through Chapter 11 of the U.S. Bankruptcy Code Operations to Continue as Normal Including Payment of Employee Wages and Benefits and Continuing Programs for Customers; Vendors and Suppliers to Receive Full Payment for Goods and Services Provided Post-Filing PHOENIX, June 10, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY) (“INSYS” or the “Company”), a specialty pharmaceutical develo...

June 10, 2019 1 EN
 PRESS RELEASE
Free
INSY Insys Therapeut...

INSYS Therapeutics Reports First Quarter 2019 Results

INSYS Therapeutics Reports First Quarter 2019 Results Company Continues to Execute Against Pipeline-Focused StrategyNew Drug Application Submitted for Proprietary Naloxone Nasal Spray FormulationCompany Provides Liquidity Update PHOENIX, May 10, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today reported financial results for its first quarter ended Mar. 31, 2019. RECENT HIGHLIGHTS Appointed Andy Long as chief executive officer; in parallel promoted A...

May 10, 2019 1 EN
 PRESS RELEASE
Free
INSY Insys Therapeut...

INSYS Therapeutics Implements Leadership Changes

INSYS Therapeutics Implements Leadership Changes Andrew G. Long Appointed Chief Executive Officer PHOENIX, April 15, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that the Board of Directors has appointed Andrew G. Long as Chief Executive Officer, effective immediately. Mr. Long succeeds Saeed Motahari, who has mutually agreed with the INSYS Board of Directors to resign as President and CEO of the Company. In connection with INSYS’ lead...

April 15, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch